Astra Logics is an innovative biotech company involved in the development of targetted drug delivery systems for the treatment
of metastatic cancer. Our breakthrough nano-particle technology has been validated across multiple clinical trials and enjoys many significant advantages over current methods.
Through our dedication to innovative science and translational research, Astra Logics has built up a portfolio of drug delivery technologies that have the potential to transform patient’s lives. Moreover, by focussing on one specific area of technology, the company is able to develop new, effective therapies rapidly, cost effectively and with lower risk relative to traditional approaches.
Astra Logics’ current areas of active research include epigenetics, immuno-oncology, protein homeostasis, biotherapeutics, and novel targets. Through advances in these fundamental areas, we will continue to address significant unmet needs, as well as provide physicians and clinicians with new options for managing patients and improving their quality of life.
Astra Logics' has created a workforce that reflects the diversity of the communities in which we do business and the patients we serve. We are united in our commitment to develop and provide life-enhancing medical technologies and make a measurable difference in the lives of millions of people. Corporate responsibility is at the core of Astra Logics' mission to transform the lives of patients with devastating cancer diseases. As we pursue this mission, we are committed to integrity, ethics and quality and are dedicated to protecting the environment and supporting the communities in which we live and work. Astra Logics was founded on the principles of integrity, ethics and sound decision-making, enabling us to sustain our company values and our commitment to putting patients first. These important concepts have and continue to provide the framework for our corporate values and the ethics of how we do business.
Cancer: The Global Killer
Cancer is now the world's second biggest killer behind cardiovascular disease. Over the last 25 years, the number of new cancer cases and cancer-related deaths has witnessed a steady increase, due to both an aging and growing global population and the continued use of highly toxic cancer treatments.
Recent studies show that cancer accounted for the loss of 196.3 million human life-years across 188 countries in 2016, with one in every three men and one in every five women being diagnosed with any one of a hundred known different types of cancerous tumour.
The major global challenge in the prevention and treatment of cancer is the effective delivery and distribution of anti-cancer drugs. While the past decade has seen some improvements in cancer therapeutics, doctors and medical professionals continue to administer out-dated and highly toxic cancer treatments and lag far behind in terms of new anti-cancer theraputic technology when compared to most other areas of medicine.
The Solution
Astra Logics' has developed a targeted, nanoscale drug delivery system optimized to treat metastatic tumors that has significant advantages over current treatment methods. Our advanced technology has the ability to target the delivery of anti-cancer drugs directly to the tumour cells, resulting in improved overall efficacy of the treatment and a better outcome for cancer patients..
Culture and Commitment
Corporate Responsibility
Compliance and Ethics